LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LN-145’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LN-145 overview

Lifileucel (LN-145) is under development for the treatment of metastatic melanoma, metastatic triple negative breast cancer, soft tissue sarcoma, osteosarcoma, bone sarcoma, chondrosarcoma, giant cell tumor of bone, anaplastic thyroid cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma and advanced or metastatic non-small cell lung cancer (NSCLC). The therapeutic candidate is administered as intravenous route. It constitutes of tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling patient robust immune response.

It was under development for the treatment of metastatic transitional cell cancer of the urothelium including renal pelvis cancer, ureters cancer, urinary bladder cancer and urethra cancer and refractory HPV-associated cancer.

Iovance Biotherapeutics overview

Iovance Biotherapeutics (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a range of cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

For a complete picture of LN-145’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.